Zepp Health Corp

Análisis de la acción Zepp Health Corp (ZEPP)

$2.770

-0.142 (-5.14%)Al cierre

Loading chart…
Máximo
2.940
Apertura
2.860
Precio medio ponderado por volumen
2.65
Volumen
161.24K
Capitalización
35.99M
Mínimo
2.230
Importe
426.74K
EV/EBITDA, TTM
-2.39

Zepp Health Corp, formerly Huami Corp, is a Netherlands-based company primarily engaged in the consumer electronics and digital health technology industry. The Company focuses on developing smart wearable devices and digital health management platforms. Their key product is the Zepp Digital Health Management Platform, which is a cloud-based system integrating smart devices, biometric sensors, Artificial Intelligence (AI) chips, and data algorithms. It aims to provide users with 24/7 actionable insights to support health, fitness, and wellness management. The platform powers a range of products including smartwatches, fitness bands, smart rings, and hearables under the Amazfit and Zepp brand names. Additionally, the Company offers AI-driven services such as Zepp Aura for sound-based wellness and Zepp Clarity for hearing health. The Company has one reportable segment: Amazfit-branded products.

www.huami.com

Análisis de IA of Zepp Health Corp (ZEPP)

Vender

Zepp Health Corp is not a good buy right now due to a current price of $3.02 and a concerning RSI of 5.838, indicating extreme oversold conditions. The company has reported a staggering year-to-date change of -89.23% and a one-year change of -93.94%, reflecting severe financial distress. Additionally, the forward P/E ratio stands at 3.124, which may seem low but is overshadowed by the company's ongoing net losses, including a net loss of $11.33 million in Q2 2026. The main risk is the widening operating loss and declining revenue expectations for Q3 2026, which could further impact stock performance.

Métricas de valoración

El PER previsto actual de Zepp Health Corp (ZEPP) es 3.12, frente a su media de 5 años de -38.30.

PER previsto

Valor razonable
Media 5A P/E
-38.30
P/E actual
3.12
Sobrevalorada
83.61
Infravalorada
-160.21

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-11.68
EV/EBITDA actual
-2.39
Sobrevalorada
22.16
Infravalorada
-45.52

Precio/ventas previsto

Valor razonable
Media 5A P/S
0.37
P/S actual
0.02
Sobrevalorada
0.96
Infravalorada
-0.22

Ballenas con ZEPP en cartera

T

Trivest Advisors Ltd

+ Con en carteraZEPP

-14.92%

Rentabilidad a 3 meses

Cronología de eventos

2026-09-22 (ET)

07:30:00

Amazfit Launches T-Rex Dual Solar Smartwatch at $649.99

2026-06-08 (ET)

21:40:00

Q1 Revenue Reaches $51.5 Million

2026-05-13 (ET)

07:30:00

Amazfit Launches Cheetah 2 Ultra at $599.99

2026-04-16 (ET)

07:10:00

Amazfit Launches Cheetah 2 Pro Sports Watch at $449.99

2026-04-15 (ET)

07:10:00

Zepp Health Signs Three-Year Global Partnership with HYROX

Noticias

Preguntas frecuentes sobre ZEPP, respondidas por Alphio AI

Zepp Health Corp, formerly Huami Corp, is a Netherlands-based company primarily engaged in the consumer electronics and digital health technology industry. The Company focuses on developing smart wearable devices and digital health management platforms. Their key product is the Zepp Digital Health Management Platform, which is a cloud-based system integrating smart devices, biometric sensors, Artificial Intelligence (AI) chips, and data algorithms. It aims to provide users with 24/7 actionable insights to support health, fitness, and wellness management. The platform powers a range of products including smartwatches, fitness bands, smart rings, and hearables under the Amazfit and Zepp brand names. Additionally, the Company offers AI-driven services such as Zepp Aura for sound-based wellness and Zepp Clarity for hearing health. The Company has one reportable segment: Amazfit-branded products. It operates in the Technology sector (ELECTRONIC COMPUTERS industry).

Zepp Health Corp is not a good buy right now due to a current price of $3.02 and a concerning RSI of 5.838, indicating extreme oversold conditions. The company has reported a staggering year-to-date change of -89.23% and a one-year change of -93.94%, reflecting severe financial distress. Additionally, the forward P/E ratio stands at 3.124, which may seem low but is overshadowed by the company's ongoing net losses, including a net loss of $11.33 million in Q2 2026. The main risk is the widening operating loss and declining revenue expectations for Q3 2026, which could further impact stock performance.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar